Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
19.50
Nov 18 • 3:59 PM ET Dollar change-0.44 Percentage change(-2.21%)
Aftermarket Close
19.50
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUI
Market Cap
5.59B
Enterprise Value
5.29B
Income
96.06M
Sales
1.05B
Book/sh
2.23
Cash/sh
2.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1846
IPO
Jun 18, 2025
P/E
57.74
Forward P/E
69.64
PEG
-
P/S
5.34
P/B
8.74
P/C
7.29
P/FCF
263.79
EV/EBITDA
32.56
EV/Sales
5.05
Quick Ratio
5.84
Current Ratio
6.71
Debt/Eq
0.72
LT Debt/Eq
0.71
Option/Short
Yes / Yes
EPS (ttm)
0.34
EPS next Y
0.28
EPS next Q
0.06
EPS this Y
127.81%
EPS next Y
147.29%
EPS next 5Y
-
EPS past 3/5Y
-7.57% -
Sales past 3/5Y
62.87% -
EPS Y/Y TTM
114.01%
Sales Y/Y TTM
61.48%
EPS Q/Q
-40.02%
Sales Q/Q
26.99%
Insider Own
55.29%
Insider Trans
-0.59%
Inst Own
54.29%
Inst Trans
1.00%
ROA
8.58%
ROE
17.19%
ROIC
8.76%
Gross Margin
69.09%
Oper. Margin
13.35%
Profit Margin
9.16%
SMA20
-31.23%
SMA50
-33.03%
SMA200
-9.66%
Trades
Shs Outstand
286.72M
Shs Float
128.21M
52W High
36.50 -46.58%
52W Low
14.19 37.42%
Volatility
7.46% 6.96%
ATR (14)
2.09
RSI (14)
24.69
Beta
1.64
Rel Volume
0.83
Avg Volume
4.70M
Volume
3,915,711
Perf Week
-20.38%
Perf Month
-37.32%
Perf Quarter
-20.67%
Perf Half Y
24.20%
Perf YTD
-27.72%
Perf Year
-17.93%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
19.94
Price
19.50
Change %
-2.21%
Consensus
Buy
Avg. Price Target
$34.23
Implied Upside
+75.5%
Analysts14incl. previous ratings
Rating Distribution10 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 09, 2026Initiated
UBS logoUUBS
Neutral$28+43.6%
Jun 02, 2026Resumed
WWolfe Research
Peer Perform
Apr 13, 2026Initiated
JEF logoJJefferies
Buy$28+43.6%
Apr 10, 2026Initiated
PPiper Sandler
Neutral$21+7.7%
Apr 01, 2026Initiated
GS logoGGoldman
Buy$27+38.5%
Feb 17, 2026Initiated
RRobert W. Baird
Outperform$26+33.3%
Dec 02, 2025Initiated
CCanaccord Genuity
Hold$28+43.6%
Jul 14, 2025Initiated
WWolfe Research
Outperform$32+64.1%
Jul 14, 2025Initiated
TD logoTTD Cowen
Buy$32+64.1%
Jul 14, 2025Initiated
JPM logoJJP Morgan
Overweight$31+59.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Denton John RusselSee RemarksSep 22 '26Sale31.827,500238,626174,855Sep 23 05:06 PM
JOHN RUSSEL DENTONOfficerSep 22 '26Proposed Sale31.827,500238,626Sep 22 04:08 PM
Brille Brian JSee RemarksSep 17 '26Option Exercise2.44400,000976,000630,303Sep 17 06:08 PM
Brille Brian JSee RemarksSep 17 '26Sale30.33400,00012,132,080230,303Sep 17 06:08 PM
BRIAN J BRILLEOfficerSep 17 '26Proposed Sale30.33400,00012,132,080Sep 17 04:34 PM
Spetzler David BaxleyPresidentSep 03 '26Option Exercise2.441,000,0002,440,0001,530,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Option Exercise2.44250,000610,0001,302,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 03 '26Sale24.86478,00011,882,9901,052,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Sale24.76119,2122,951,1171,182,871Sep 04 04:59 PM
DAVID SPETZLEROfficerSep 04 '26Proposed Sale24.76119,2122,951,117Sep 04 04:43 PM
DAVID SPETZLEROfficerSep 03 '26Proposed Sale24.86478,00011,882,984Sep 03 04:45 PM
GEORGE H POSTE REVOCABLE TRUSTFormer AffiliateAug 24 '26Proposed Sale26.06100,0002,606,320Aug 24 04:29 PM
GEORGE H POSTEDirectorAug 07 '26Proposed Sale21.4230,000642,633Aug 07 05:12 PM
GEORGE H POSTEDirectorAug 03 '26Proposed Sale16.2520,000325,000Aug 03 04:10 PM
HALBERT JONDirectorMay 15 '26Buy14.5668,000990,080704,598Jul 13 07:06 AM
Vacirca Jeff LDirectorMay 11 '26Buy16.1531,050501,42649,671May 12 08:22 AM
CASTLEMAN PETER MDirectorJan 09 '26Option Exercise18.602,50046,50018,629Jan 13 06:37 PM
Power Luke ThomasSee RemarksDec 11 '25Option Exercise2.4462,250151,890161,821Dec 12 07:39 PM
Power Luke ThomasSee RemarksDec 11 '25Sale26.5862,2501,654,46199,571Dec 12 07:39 PM
LUKE POWEROfficerDec 11 '25Proposed Sale27.1062,2501,686,975Dec 11 04:27 PM
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.
ChairmanDr. David Dean Halbert M.D.
Executive Vice Chairman & Executive VPMr. Brian J. Brille J.D.
M.S.Dr. David Spetzler M.B.A.
Senior VPMr. J. Russel Denton
Senior VPMr. Luke Power